CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 420 enrolled
Drug / intervention
NRP104drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00334880
NCT00334880Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group, Forced Dose Titration, Safety and Efficacy Study of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

New River Pharmaceuticals·interventional·Posted Jun 8, 2006·Updated Jul 2, 2009

In Brief

A Phase 3 clinical trial evaluating NRP104 for Attention Deficit Hyperactivity Disorder and 2 related conditions. Completed, enrolled 420 participants across 48 sites.

Detailed Summary

The purpose of this study is to evaluate the safety and effectiveness of NRP104 administered as a daily morning dose (30, 50, and 70mg/day) compared to placebo in adults (18-55 years of age inclusive) diagnosed with moderate to severe Attention Deficit Hyperactivity Disorder (ADHD).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 8, 2006
Enrollment StartMay 1, 2006
Study CompletionNov 1, 2006
TodayJul 2, 2026
Posted 20.1 years ago

Interventions

NRP104drug